GlaxoSmithKline (GSK) has entered into a significant partnership with LTZ Therapeutics to develop innovative treatments targeting hematologic cancers and solid tumors. This collaboration will leverage LTZ’s...
ViiV Healthcare has announced that its long-acting HIV pre-exposure prophylaxis (PrEP) therapy, cabotegravir, demonstrated superior acceptability among patients compared to Gilead Sciences‘ lenacapavir in an early-stage...
